Lack of association of NAMPT rs9770242 and rs59744560 polymorphisms with disease susceptibility and cardiovascular risk in patients with rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 29, Issue 4, 2011, Pages 681-688

  Garcia Bermudez M ^a   Gonzalez Juanatey C ^b   Rodriguez Rodriguez L ^c   Miranda Filloy, J A ^b   Perez Esteban, S ^d   Vazquez Rodriguez, T R ^b   Castaneda S ^d   Balsa, A ^e   Fernandez Gutierrez B ^c   Llorca, J ^f   Gonzalez Alvaro I ^d   Martin J ^a   Gonzalez Gay M A ^g  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL XERAL CALDE   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f UNIVERSITY OF CANTABRIA   (Spain)

^g HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Atherosclerosis; Cardiovascular disease; Genetics; Rheumatoid arthritis

Indexed keywords

HLA DRB1 ANTIGEN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; CYTOKINE; HLA DR ANTIGEN; HLA-DRB1 ANTIGEN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE, HUMAN;

ADULT; AGED; ALLELE; ARTERY BLOOD FLOW; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; ATHEROSCLEROSIS; B SCAN; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIUM; FEMALE; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAMPT GENE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; VASODILATATION; ANALYSIS OF VARIANCE; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; ECHOGRAPHY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; INTIMA; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHENOTYPE; PROMOTER REGION; RISK; RISK ASSESSMENT; RISK FACTOR; SPAIN; STATISTICAL MODEL; TUNICA MEDIA;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTHRITIS, RHEUMATOID; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CYTOKINES; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HLA-DR ANTIGENS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; ODDS RATIO; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK ASSESSMENT; RISK FACTORS; SPAIN; TUNICA INTIMA; TUNICA MEDIA; VASODILATION;

EID: 80055096095     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, MARTIN J: Rheumatoid arthritis: adisease associated with accelerated atherogenesis. Semin Arthritis Rheum 2005; 35: 8-17.
2. DEL RINCÓN I, ESCALANTE A: Atherosclerotic cardiovascular disease in rheumatoid arthritis. Curr Rheumatol Rep 2003; 5: 278-86.
3. DEL RINCÓN I, WILLIAMS K, STERN MP, FREEMAN GL, ESCALANTE A: High incidence of cardiovascular events in rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001; 44: 2737-45.
4. DESSEIN PH, JOFFE BI, VELLER MG et al.: Traditional and nontraditional cardiovascular risk factors are associated with atherosclerosis in rheumatoid arthritis. J Rheumatol 2005; 32: 435-42.
5. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, LOPEZ-DIAZ MJ et al.: HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57: 125-32.
6. SATTAR N, MCCAREY DW, CAPELL H, MCINNES IB: Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003; 108: 2957-63.
7. GONZALEZ-JUANATEY C, TESTA A, GARCIACASTELO A et al.: HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114: 647-52.
8. PALOMINO-MORALES R, GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR et al.: Interleukin-6 gene -174 promoter polymorphism is associated with endothelial dysfunction but not with disease susceptibility in patients with rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 964-70.
9. PALOMINO-MORALES R, GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR et al.: A1298C polymorphism in the MTHFR gene predisposes to cardiovascular risk in rheumatoid arthritis. Arthritis Res Ther 2010; 12: R71.
10. MATTEY DL, THOMSON W, OLLIER WE et al.: Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007; 56: 1408-16.
11. FARRAGHER TM, GOODSON NJ, NASEEM H Et Al.: Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58: 359-69.
12. FUKUHARA A, MATSUDA M, NISHIZAWA M et al.: Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-30.
13. SAMAL B, SUN Y, STEARNS G, XIE C, SUGGS S, MCNIECE I: Cloning and characterization of the cDNA encoding a novel human pre-Bcell colony-enhancing factor. Mol Cell Biol 1994; 14: 1431-7.
14. RONGVAUX A, SHEA RJ, MULKS MH et al.: Pre-B-cell colony-enhancing factor, whose expression is up-regulated inu activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol 2002; 32: 3225-34.
15. NOWELL MA, RICHARDS PJ, FIELDING CA et al.: Regulation of pre-B cell colonyenhancing factor by STAT-3-dependent interleukin- 6 trans-signaling: implications in the pathogenesis of rheumatoid arthritis. Arthritis Rheum 2006; 54: 2084-95.
16. JIA SH, LI Y, PARODO J, KAPUS A et al.: Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis. J Clin Invest 2004; 113: 1318-27.
17. MOSCHEN AR, KASER A, ENRICH B, MOSHEIMER B et al.: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-58.
18. ROMACHO T, AZCUTIA V, VAZQUEZ-BELLA M et al.: Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signaling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetología 2009; 52: 2455-63.
19. GUZIK TJ, MANGALAT D, KORBUT R: Adipocytokines - novel link between inflammation and vascular function? J Physiol Pharmacol 2006; 57: 505-28.
20. LAGO F, DIEGUEZ C, GOMEZ-REINO JJ, GUALILLO O: The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor ev 2007; 18: 313-25.
21. BRENTANO F, SCHORR O, OSPELT C et al.: Pre-B cell colony-enhancing factor/ visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matriz degrading activities. Arthritis Rheum 2007; 56: 2829-39.
22. OTERO M, LAGO R, GÓMEZ R, LAGO F et al.: Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65: 1198-201.
23. RHO YH, SOLUS J, SOKKA T et al.: Adipocytokines are associated with radiographic joint damage in Rheumatoid Arthritis. Arthritis Rheum 2009; 60: 1906-14.
24. ZHANG YY, GOTTARDO L, THOMPSON R et al.: A Visfatin promoter polymorphism is associated with low-grade inflammation and type 2 diabetes. Obesity 2006; 14: 2119-26.
25. BAILEY SD, LOREDO-OSTI JC, LEAGE P, FAITH J: Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French- Canadian population. Diabetes 2006; 55: 2896-902.
26. JOHANSSON LM, JOHANSSON LE, RIDDERSTRÄLE M: The visfatin (PBEF1) G-948T gene polymorphism is associated with increased high density lipoprotein cholesterol in obese subjects. Metabolism 2008; 57: 1558-62.
27. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
28. HO KK, PINSKY JL, KANNEL WB, LEVY D: The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993; 22: 6A-13A.
29. GONZALEZ-JUANATEY C, LLORCA J, MARTIN J, GONZALEZ-GAY MA: Carotid intimamedia thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009; 38: 366-71.
30. GONZALEZ-JUANATEY C, LLORCA J, MIRANDA- FILLOY JA et al.: Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 287-93.
31. GONZALEZ-GAY MA, GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR, MARTIN J, LLORCA J: Endothelial dysfunction, carotid intima-media thickness, and accelerated atherosclerosis in rheumatoid arthritis. Semin Arthritis Rheum 2008; 38: 67-70.
32. GONZALEZ-JUANATEY C, LLORCA J, GARCIA- PORRUA C, MARTIN J, GONZALEZ-GAY MA: Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. Arthritis Rheum 2006; 55: 150-3.
33. GONZALEZ-JUANATEY C, LLORCA J, AMIGO- DIAZ E et al.: High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007; 57: 1074-80.
34. GREGERSEN PK, SILVER J, WINCHESTER RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
35. GONZALEZ-GAY MA, GARCIA-PORRUA C, HAJEER AH: Influence of human leukocyte antigen-DRB1 on the susceptibility and severity of rheumatoid arthritis. Semin Arthritis Rheum 2002; 31: 355-60.
36. SKOL AD, SCOTT LJ, ABECASIS GR, BOEHNKE M: Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat Genet 2006; 38: 209-13.
37. CARMONA L, VILLAVERDE V, HERNÁNDEZGARCÍA C, BALLINA J, GABRIEL R, LAFFON A; EPISER STUDY GROUP: The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford). 2002; 41: 88-95.
38. DUDBRIDGE F: Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered 2008; 66: 87-98.
39. CURAT CA, WEGNER V, SENGENES C et al.: Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. Diabetologia 2006; 49: 744-7.
40. CHENG CP, LONG AG, SOLUS JF et al.: Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009; 18: 799-806.
41. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, GARCIA-UNZUETA MT et al.: Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp Rheumatol 2010; 28: 56-62.
42. LIU SW, QIAO SB, YUAN JS, LIU DQ: Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxford) 2009; 71: 202-7.
43. DAHL TB, YNDESTAD A, SKJELLAND M, ØIE E, DAHL A, MICHELSEN A et al.: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization. Circulation 2007; 115; 972-80.
44. ZHONG M, TAN HW, GONG HP, WANG SF, ZHANG Y, ZHANG W: Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008; 69: 878-84.
45. GONZALEZ-GAY MA, LLORCA J, PALOMINOMORALES R, GOMEZ-ACEBO I, GONZALEZJUANATEY C, MARTIN J: Influence of nitric oxide synthase gene polymorphisms on the risk of cardiovascular events in rheumatoid arthritis. Clin Exp Rheumatol 2009; 27: 116-9.
46. RODRÍGUEZ-RODRÍGUEZ L, GONZÁLEZJUANATEY C, ROGELIO PALOMINO-MORALES R et al.: TNFA -308 (rs1800629) polymorphism is associated with a higher risk of cardiovascular disease in patients with rheumatoid arthritis. Atherosclerosis 2011; 216: 125-30.
47. OROZCO G, RUEDA B, MARTIN J: Genetic basis of rheumatoid arthritis. Biomed Pharmacother 2006; 60: 656-62.
48. PALOMINO-MORALES R, GONZÁLEZJUANATEY C, VAZQUEZ-RODRIGUEZ TR, GONZÁLEZ-GAY MA: Lack of association of PTPN22, STAT4 and TRAF1/C5 gene polymorphisms with cardiovascular risk in rheumatoid arthritis. Clin Exp Rheumatol 2010; 28: 695-701.
49. PALOMINO-MORALES R, GONZALEZ-JUANATEY C, VAZQUEZ-RODRIGUEZ TR et al.: Lack of association between macrophage migration inhibitory factor-173 gene polymorphism with disease susceptibility and cardiovascular risk in rheumatoid arthritis patients from Northwestern Spain. Clin Exp Rheumatol 2010; 28: 68-72.
50. RODRÍGUEZ-RODRÍGUEZ L, GARCÍA-BERMÚDEZ M, GONZÁLEZ-JUANATEY C et al.: Vascular Endothelial Growth Factor A and cardiovascular disease in rheumatoid arthritis patients. Tissue Antigens 2011; 77: 291-7.
51. RODRÍGUEZ-RODRÍGUEZ L, GARCÍA-BERMÚDEZ M, GONZÁLEZ-JUANATEY C et al.: Lack of association between ADIPOQ rs266729 and ADIPOQ rs1501299 polymorphisms and cardiovascular disease in rheumatoid arthritis patients. Tissue Antigens 2011; 77: 74-8.
52. GARCÍA-BERMÚDEZ M, GONZÁLEZ-JUAN ATEY C, RODRÍGUEZ-RODRÍGUEZ L et al.: Lack of association between LEP rs2167270 (19G>A) polymorphism and disease susceptibility and cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 293-8.
53. RODRÍGUEZ-RODRÍGUEZ L, GARCÍA-BERMÚDEZ M, GONZÁLEZ-JUANATEY C et al.: Lack of association between RETN rs1862513 polymorphism and cardiovascular disease in rheumatoid arthritis patients. Clin Exp Rheumatol 2011; 29: 19-25.
54. RODRÍGUEZ-RODRÍGUEZ L, GARCÍA-BERMÚDEZ M, GONZÁLEZ-JUANATEY C et al.: Analysis of the influence of the Ghrelin Receptor rs509035, rs512692 and rs2922126 polymorphisms in the risk of cardiovascular disease in patients with rheumatoid arthritis. Clin Exp Rheumatol 2011; 29: 142-3.